

**DIVISION OF OTC DRUG PRODUCTS
CENTER FOR DRUG EVALUATION AND RESEARCH**

ANNOUNCEMENT OF OTC DRUG FEEDBACK MEETING

FROM: EEN:

Representatives of FDA

and

2031 '98 JUN 15 P12:15

The Nonprescription Drug Manufacturers Association

**R. William Soller, Ph.D., Senior Vice President and
Director of Science & Technology**

Patrice B. Wright, Ph.D., Director, Pharmacology & Toxicology

Del Pharmaceuticals, Inc.

Charles Hinkaty, President

Joseph A. Kanapka, Ph.D., Senior Vice-President, Scientific Affairs

William Thompson, Ph.D., Consultant in Biostatistics

William E. Cooley, Ph.D., President, Cooley Consulting, Inc.

The Mentholatum Company

Henry Chan, Ph.D., Director of Product Development,

Sandra Cohen Kalter, Counsel, King & Spalding

Whitchall-Robins Healthcare

Joanne Robinett, Director, Regulatory Affairs

Joel Waksman, Ph.D., Senior Director,

Biostatistics & Data Management

Jamie Greene, Ph.D., Senior Director, Clinical Research

Elliot Hersh, D.M.D., Ph.D., Consultant

Mentholatum Research Laboratories, Inc.

Robert O'Connor, Ph.D., President

80N-0295

MM102

TOPIC: Effectiveness of OTC products containing either benzocaine or eugenol in the relief of toothache.

DATE: June 25, 1998

TIME: 1:00 p.m.

LOCATION: Conference Room S-400
9201 Corporate Boulevard
Rockville, Maryland

Pursuant to the agency's policy statement published in the FEDERAL REGISTER of September 29, 1981 (46 FR 47740) and clarified April 1, 1983 (48 FR 14050) and February 4, 1985 (50 FR 4916), which includes provisions for agency meetings with industry or other interested persons, this feedback meeting is being announced.

All feedback meetings are open to the public and no prior reservation is necessary. For further information or to reconfirm that the meeting has not been rescheduled or canceled, call Stephanie Mason, 301-827-2222.

ATTENTION: JENNIE BUTLER

cc: Docket No. 80N-0295 JUN 15 1998

DATE FORWARDED: _____